Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma
Status:
Terminated
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well pazopanib hydrochloride works in treating patients with
advanced or progressive malignant pheochromocytoma or paraganglioma. Pazopanib hydrochloride
may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and
by blocking blood flow to the tumor.